Implementation of Substance Use Treatment in Ambulatory Care

Describes the core elements of SBIRT programs and provides general administrative and managerial information relevant to implementing SBIRT services, including effectiveness, implementation models, challenges and barriers to implementation, issues of cost and sustainability, real-life program anecdotes, and case studies.

Provides substance abuse treatment providers with updated information on co-occurring substance use and mental disorders and advances in treatment for people with co-occurring disorders. Discusses terminology, assessment, and treatment strategies and models.

Guides physicians to incorporate screening, brief interventions, and referrals to treatment for use of alcohol, tobacco, marijuana, and other drugs among adolescent patients.

Details a checklist for providers to use when determining if a patient meets the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, criteria for a diagnosis of opioid use disorder.

Reviews three FDA-approved medications for OUD treatment (methadone, naltrexone, and buprenorphine) and the other strategies and services needed to support people in recovery.

Identifies patient problems and concerns attributed to use of opioids, rather than focusing on aberrant behaviors.

Assists in the prediction of aberrant drug-related behavior among patients with chronic pain.

Helps clinicians identify whether a long-term chronic pain patient is exhibiting aberrant behaviors associated with opioid medication misuse.

Assesses for SUD risk among adolescents 12-17 years old.

Provides electronic screening tools for adolescent substance use that triage adolescents ages 12-17 into three levels of risk for SUD based on their report of past year use: no reported use, lower risk, and higher risk.